Search


Current filters:


Clear current filters  or Add more filters

View Option



Results 11-20 of 21 (Search time: 0.089 seconds).

  Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia (Journal article)

  Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetyllhydrolase (Journal article)

  Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect (Journal article)

  Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures (Journal article)

  Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia (Journal article)

  Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase (Journal article)

  EFFECT OF STANDARD COMBINATION OF VALSARTAN WITH EITHER AMLODIPINE OR HYDROCHLOROTHIAZIDE ON LDL SUBFRACTION PROFILE IN PATIENTS WITH HYPERTENSION (Journal article)

  Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension (Journal article)

  Effect of rosuvastatin on low density lipoprotein (LDL) profile in patients with primary dyslipidaemia (Journal article)

  Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia (Journal article)